Liquid Biopsy Market Size, Share, Growth, and Forecast 2025–2035

The Liquid Biopsy Market is gaining momentum as healthcare providers increasingly seek diagnostic approaches that are less invasive, repeatable, and capable of providing molecular information. Liquid biopsy analyzes biomarkers found in biological fluids, particularly blood, to identify genetic and cellular signals associated with cancer and other diseases. Its potential to complement or reduce reliance on conventional tissue sampling is creating new opportunities across clinical diagnostics.

WiseGuyReports estimates that the market reached USD 8.8 billion in 2024 and is projected to grow from USD 9.9 billion in 2025 to USD 29.7 billion by 2035, representing a CAGR of 11.6%. Key market dynamics include technological advancements, increasing cancer prevalence, demand for non-invasive procedures, rising research and development investment, and the expanding role of personalized medicine.

Cancer diagnostics remain at the center of liquid biopsy adoption. Oncology applications can use circulating tumor DNA and circulating tumor cells to obtain information about tumors without requiring repeated invasive tissue procedures. This capability is particularly valuable for monitoring disease progression and evaluating treatment response over time. Liquid biopsy can also provide molecular information that helps researchers and clinicians understand changes in tumor biology.

The development of next-generation sequencing and digital PCR has enhanced the analytical capabilities of liquid biopsy platforms. These technologies enable the detection and analysis of genetic alterations with increasing sensitivity. As testing platforms become more sophisticated, their potential applications are expanding beyond established diagnostic uses toward early detection, therapy selection, recurrence monitoring, and residual disease assessment.

The market is also supported by expanding research collaborations. WiseGuyReports identifies companies including Guardant Health, Exact Sciences, Illumina, Roche, Freenome, GRAIL, and others as participants in the competitive landscape. Recent industry activity has included collaborations and technology development focused on ctDNA analysis and multi-cancer early detection.

North America continues to represent a major regional market, supported by established healthcare infrastructure and strong investment in precision medicine. Europe is also progressing through research activity and regulatory support, while Asia-Pacific offers considerable growth potential as healthcare investment and awareness of advanced cancer diagnostics increase.

With continued innovation in biomarker detection and genomic analysis, the Liquid Biopsy Market is positioned to become increasingly important in personalized healthcare and modern cancer management.